21 CFR 212.20: What activities must I perform to ensure drug quality?

Requires PET drug producers to oversee production, approve or reject materials and any specification or process changes, review production records and investigate errors or failures, and follow written quality assurance procedures.

Part 212, Current Good Manufacturing Practice for Positron Emission Tomography Drugs · Subpart C, Quality Assurance

Recent 483s citing 212.20

See all 483s citing 212.20

The regulation text

§ 212.20 What activities must I perform to ensure drug quality?.

(a)Production operations. You must oversee production operations to ensure that each PET drug meets the requirements of the act as to safety and has the identity and strength, and meets the quality and purity characteristics, that it is supposed to have.

(b)Materials. You must examine and approve or reject components, containers, closures, in-process materials, packaging materials, labeling, and finished dosage forms to ensure compliance with procedures and specifications affecting the identity, strength, quality, or purity of a PET drug.

(c)Specifications and processes. You must approve or reject, before implementation, any initial specifications, methods, processes, or procedures, and any proposed changes to existing specifications, methods, processes, or procedures, to ensure that they maintain the identity, strength, quality, and purity of a PET drug. You must demonstrate that any change does not adversely affect the identity, strength, quality, or purity of any PET drug.

(d)Production records. You must review production records to determine whether errors have occurred. If errors have occurred, or a production batch or any component of the batch fails to meet any of its specifications, you must determine the need for an investigation, conduct investigations when necessary, and take appropriate corrective actions.

(e)Quality assurance. You must establish and follow written quality assurance procedures.

Questions

What does 21 CFR 212.20 require?

Requires PET drug producers to oversee production, approve or reject materials and any specification or process changes, review production records and investigate errors or failures, and follow written quality assurance procedures.

Which sections are cited alongside 212.20?

In the same 483s, investigators most often also cite 212.50 (What production and process controls must I have?), 212.30 (What requirements must my facilities and equipment meet?), 212.60 (What requirements apply to the laboratories where I test components, in-process materials, and finished PET drug products?).